(UroToday.com) The 2021 ASCO annual meeting’s poster discussion session for prostate cancer included a discussant presentation by Dr. Julie Graff discussing novel approaches to metastatic prostate cancer.
Dr. Graff notes that over the last decade we have made significant strides in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with several new agents available, relying heavily on the androgen receptor inhibitors, namely enzalutamide and abiraterone: